Fibrinogen human

Identification

Summary

Fibrinogen human is a hemostatic agent used for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Brand Names
Artiss, Evarrest, Evicel, Fibryga, Riastap, Tachosil, Tisseel, Vistaseal
Generic Name
Fibrinogen human
DrugBank Accession Number
DB09222
Background

Fibrinogen concentrate (human) is a hematological agent. It works by replacing a certain protein in the blood that helps with blood clotting. Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa. It is a physiological substrate for three enzymes: plasmin, factor XIIIa and thrombin. It is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Blood factors
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Coagulation Factor I
  • Factor I (fibrinogen)
  • Factor I human
  • Fibrinogen
  • Fibrinogen (human)
  • Fibrinogen Concentrate (Human)
  • Fibrinogen concentrate human
  • Fibrinogen human
  • Fibrinogen human plasma-derived
  • Fibrinogen, human
  • Human fibrinogen

Pharmacology

Indication

For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Fibrinogen replaces the missing, or low coagulation factor.

Mechanism of action

Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa. The native molecule is a dimer and consists of three pairs of polypeptide chains (Aα, Bβ and γ). Fibrinogen is a physiological substrate of three enzymes: thrombin, factor XIIIa, and plasmin. During the coagulation process, thrombin cleaves the Aα and Bβ chains releasing fibrinopeptides A and B (FPA and FPB, respectively). FPA is separated rapidly and the remaining molecule is a soluble fibrin monomer (fibrin I). The slower removal of FPB results in formation of fibrin II that is capable of polymerization that occurs by aggregation of fibrin monomers. The resulting fibrin is stabilized in the presence of calcium ions and by activated factor XIII, which acts as a transglutaminase. Factor XIIIa-induced cross-linking of fibrin polymers renders the fibrin clot more elastic and more resistant to fibrinolysis. Cross-linked fibrin is the end result of the coagulation cascade, and provides tensile strength to a primary hemostatic platelet plug and structure to the vessel wall.

Absorption

Cmax is 140 mg/dL

Volume of distribution

Mean volume of distribution is 52.7 mL/kg.

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

78.7 hours

Clearance

0.59 mL/h/kg

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Abciximab.
AcenocoumarolThe therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Acenocoumarol.
Alpha-1-proteinase inhibitorThe therapeutic efficacy of Fibrinogen human can be increased when used in combination with Alpha-1-proteinase inhibitor.
AlteplaseThe therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Alteplase.
Aminocaproic acidThe risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Fibrinogen human.
AncrodThe therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Ancrod.
AnistreplaseThe therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Anistreplase.
Antithrombin AlfaThe therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Antithrombin Alfa.
Antithrombin III humanThe therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Antithrombin III human.
ApixabanThe therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Apixaban.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
No interactions found.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
FibrygaPowder, for solution1 g / vialIntravenousOctapharma Pharmazeutika Produktionsges M B H2018-08-08Not applicableCanada flag
FibrygaKit20 mg/1mLIntravenousOctapharma USA Inc2017-10-16Not applicableUS flag
RiaSTAPInjection, powder, lyophilized, for solution1300 mg/50mLIntravenousCSL Behring GmbH2009-01-16Not applicableUS flag
RiaSTAPPowder, for solution1000 mg / vialIntravenousCsl Behring2013-01-31Not applicableCanada flag
RiaSTAPInjection, powder, lyophilized, for solution1300 mg/50mLIntravenousCSL Behring GmbH2009-01-162009-03-17US flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ArtissFibrinogen human (90 mg/1mL) + Human thrombin (4 [iU]/1mL)KitTopicalBaxalta US Inc.2008-03-212008-03-21US flag
ArtissFibrinogen human (125 mg / mL) + Aprotinin (3000 kiu / mL) + Calcium chloride (40 mcmol / mL) + Human thrombin (4 unit / mL)SolutionTopicalBaxter Laboratories2011-12-18Not applicableCanada flag
ARTISS 10 ML ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTOR, 1 ADETFibrinogen human (91 mg/ml) + Aprotinin (3000 KIU/ml) + Calcium chloride dihydrate (40 mcmol/ml) + Thrombin (4 IU/ml)SolutionTopicalBAXTER TURKEY RENAL HİZMETLER A.Ş.2020-08-14Not applicableTurkey flag
ARTISS 2 ML ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTOR, 1 ADETFibrinogen human (91 mg/ml) + Aprotinin (3000 KIU/ml) + Calcium chloride dihydrate (40 mcmol/ml) + Thrombin (4 IU/ml)SolutionTopicalBAXTER TURKEY RENAL HİZMETLER A.Ş.2020-08-14Not applicableTurkey flag
ARTISS 4 ML ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTOR, 1 ADETFibrinogen human (91 mg/ml) + Aprotinin (3000 KIU/ml) + Calcium chloride dihydrate (40 mcmol/ml) + Thrombin (4 IU/ml)SolutionTopicalBAXTER TURKEY RENAL HİZMETLER A.Ş.2020-08-14Not applicableTurkey flag
ARTISS Fibrin SealantFibrinogen human (90 mg/1mL) + Human thrombin (4 [iU]/1mL)SolutionTopicalBaxter Healthcare Corporation2008-03-19Not applicableUS flag
ARTISS FrozenFibrinogen human (90 mg/1mL) + Human thrombin (4 [iU]/1mL)SolutionTopicalBaxalta US Inc.2009-03-192019-06-30US flag
BERIPLAST-P COMBI SET 1 ML TROMBİN ÇÖZELTİSİ VE 1 ML FİBRİNOJEN ÇÖZELTİSİ İÇEREN FİBRİN YAPIŞTIRICIFibrinogen human (90 mg/ml) + Antihemophilic factor human (60 IU/ml) + Aprotinin (1000 KIU/ml) + Calcium chloride dihydrate (5.9 mg/ml) + Thrombin (500 IU/ml)SolutionCSL BEHRİNG BİYOTERAPİ İLAÇ DIŞ TİC. A.Ş.2020-08-14Not applicableTurkey flag
BERIPLAST-P COMBI SET 3 ML TROMBİN ÇÖZELTİSİ VE 1 ML FİBRİNOJEN ÇÖZELTİSİ İÇEREN FİBRİN YAPIŞTIRICIFibrinogen human (90 mg/ml) + Antihemophilic factor human (60 IU/ml) + Aprotinin (1000 KIU/ml) + Calcium chloride dihydrate (5.9 mg/ml) + Thrombin (500 IU/ml)SolutionCSL BEHRİNG BİYOTERAPİ İLAÇ DIŞ TİC. A.Ş.2020-08-14Not applicableTurkey flag
EvarrestFibrinogen human (8.6 mg/1cm2) + Human thrombin (37.5 [iU]/1cm2)PatchTopicalEthicon, Inc.2013-03-01Not applicableUS flag

Categories

ATC Codes
B02BB01 — Fibrinogen, human
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
N94833051K
CAS number
9001-32-5

References

General References
  1. FDA label [Link]
PubChem Substance
347910418
RxNav
4385
Drugs.com
Drugs.com Drug Page
Wikipedia
Fibrin_glue
AHFS Codes
  • 20:28.16 — Hemostatics
FDA label
Download (201 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedNot AvailableBlood Clotting / Blood Platelet Transfusion1
4CompletedPreventionBleeding Disorders / Fibrinogen Deficiency / Hypofibrinogenemia1
4CompletedPreventionBleeding / General Surgery / Scoliosis; Adolescence1
4CompletedPreventionOsteoarthritis (OA)1
4CompletedPreventionProstate or Bladder Cancer1
4CompletedTreatmentAspiration / Breast Cancer / Seroma1
4CompletedTreatmentBleeding Disorders / Fibrinogen; Deficiency, Acquired / Traumas1
4CompletedTreatmentBlood Loss1
4CompletedTreatmentCardiovascular Surgery / Hemorrhage / Hemostasis1
4CompletedTreatmentCervical Cancers / Endometrial Cancer / Lymphoceles1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionTopical
Solution
Kit; solutionTopical
SolutionIntralesional; Irrigation
Injection, powder, for solutionParenteral
Powder, for solutionIntravenous
Solution
InjectionIntravenous
KitIntravenous20 mg/1mL
Powder, for solutionIntravenous1 g / vial
PowderTopical
Injection, powder, lyophilized, for solutionIntravenous1300 mg/50mL
Powder, for solutionIntravenous1000 mg / vial
Powder, for solutionTopical
PatchTopical
SpongeTopical
KitTopical
Kit; solution
PowderSoft tissue
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created on October 22, 2015 19:51 / Updated on June 16, 2021 00:22